Brief: Kintor Pharmaceutical Announces Top-Line Data Of Phase III Study Of COVID-19 Drug
06/04/2022 01:20
April 6 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* ANNOUNCES TOP-LINE DATA OF PHASE III STUDY OF
PROXALUTAMIDE IN
TREATING OUTPATIENTS WITH MILD TO MODERATE COVID-19
Source text for Eikon: ID:nHKSbT8ttt
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint